摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-[[5-Chloro-3-(3-methylpyridazin-4-yl)oxypyridin-2-yl]amino]-1,3-thiazol-4-yl]ethane-1,2-diol | 1138671-69-8

中文名称
——
中文别名
——
英文名称
1-[2-[[5-Chloro-3-(3-methylpyridazin-4-yl)oxypyridin-2-yl]amino]-1,3-thiazol-4-yl]ethane-1,2-diol
英文别名
——
1-[2-[[5-Chloro-3-(3-methylpyridazin-4-yl)oxypyridin-2-yl]amino]-1,3-thiazol-4-yl]ethane-1,2-diol化学式
CAS
1138671-69-8
化学式
C15H14ClN5O3S
mdl
——
分子量
379.827
InChiKey
GRYOVMOBQZDVNR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    25
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    142
  • 氢给体数:
    3
  • 氢受体数:
    9

文献信息

  • Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
    申请人:Aicher Thomas Daniel
    公开号:US20100204240A1
    公开(公告)日:2010-08-12
    Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    提供的化合物式(I)如下:其中R2、R3、R13、L和D2如规范中所定义,这些化合物可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或紊乱,包括但不限于糖尿病、糖耐量受损、IFG(空腹血糖受损)和IFG(空腹高血糖),以及本文所讨论的其他疾病和紊乱。
  • Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
    申请人:AICHER Thomas Daniel
    公开号:US20120277242A1
    公开(公告)日:2012-11-01
    Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    本发明提供了式(I)的化合物:其中R2、R3、R13、L和D2如规范中所定义,它们在治疗和/或预防由葡萄糖激酶活性不足介导的疾病或疾病中有用,或者可以通过激活葡萄糖激酶来治疗,包括但不限于糖尿病、糖耐量受损、IFG(空腹血糖受损)和IFG(空腹高血糖),以及其他疾病和疾病,如在此处所讨论的。
  • COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES
    申请人:Ashton Kate
    公开号:US20120225854A1
    公开(公告)日:2012-09-06
    The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    本发明涉及公式I的化合物或其药学上可接受的盐,其与葡萄糖激酶调节蛋白相互作用。此外,本发明涉及使用这些化合物或其药学上可接受的盐以及含有这些化合物或其药学上可接受的盐的药物组合物治疗2型糖尿病以及其他与葡萄糖激酶调节蛋白有关的疾病和/或病况的方法。
  • BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES
    申请人:Bartberger Michael David
    公开号:US20140155415A1
    公开(公告)日:2014-06-05
    The present invention relates to compounds of formula I or II, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    本发明涉及公式I或II的化合物,或其药学上可接受的盐,其与葡萄糖激酶调节蛋白相互作用。此外,本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或状况的方法,以及含有这些化合物或其药学上可接受的盐的制药组合物。
  • INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES
    申请人:Array BioPharma Inc.
    公开号:US20150057448A1
    公开(公告)日:2015-02-26
    Provided are intermediates having the formulas wherein R 2 , R 3 , and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.
    提供了中间体的公式,其中R2,R3和L的定义如规范中所述,这些中间体在制备吡啶-2-基基-1,2,4-噻二唑生物中很有用。
查看更多